Casdin Capital LLC Acquires New Shares in Taysha Gene Therapies, Inc. $TSHA

Casdin Capital LLC acquired a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,500,000 shares of the company’s stock, valued at approximately $8,250,000. Taysha Gene Therapies comprises about 0.5% of Casdin Capital LLC’s investment portfolio, making the stock its 28th largest position. Casdin Capital LLC owned 0.55% of Taysha Gene Therapies at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Balyasny Asset Management L.P. acquired a new stake in Taysha Gene Therapies during the fourth quarter valued at $231,000. Guggenheim Capital LLC acquired a new stake in Taysha Gene Therapies during the fourth quarter valued at $61,000. J. Goldman & Co LP acquired a new stake in Taysha Gene Therapies during the fourth quarter valued at $186,000. AQR Capital Management LLC boosted its position in Taysha Gene Therapies by 11.8% during the fourth quarter. AQR Capital Management LLC now owns 168,862 shares of the company’s stock valued at $929,000 after purchasing an additional 17,862 shares during the last quarter. Finally, Cetera Investment Advisers boosted its position in Taysha Gene Therapies by 30.9% during the fourth quarter. Cetera Investment Advisers now owns 21,154 shares of the company’s stock valued at $116,000 after purchasing an additional 4,992 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA opened at $6.19 on Thursday. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -16.29 and a beta of 1.19. The company’s fifty day moving average is $5.86 and its two-hundred day moving average is $5.20. Taysha Gene Therapies, Inc. has a 52-week low of $2.25 and a 52-week high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on TSHA shares. Needham & Company LLC lifted their price objective on Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, March 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Finally, Canaccord Genuity Group boosted their price target on Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, April 6th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $11.64.

Insider Transactions at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the sale, the insider directly owned 1,136,410 shares in the company, valued at $5,068,388.60. This trade represents a 14.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is owned by corporate insiders.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.